| Background: At present,the incidence of coronary artery disease has been increasing year by year,becoming a major threat to human life and safety.Research data show that cardiovascular disease may become the leading cause of death among Chinese residents.Therefore,prevention and treatment of coronary heart disease are of great significance to the health of Chinese residents.Currently,coronary stenting is the most common and effective treatment for cardiovascular disease.During the development of coronary stents,bare metal stents,metal drug-eluting stents and degradable stents were successively introduced.Because bare metal and drug-eluting stents show good therapeutic efficacy in multi-faceted clinical practice,as well as material-science limitations in the past,the development of biodegradable stents has been limited and rarely enters the research field.With the increasing number of patients with coronary heart disease in recent years,and the age of onset is gradually younger,biodegradable stent due to its unique advantages can be completely degraded and has attracted widespread attention,with advances in materials science in recent years,the clinical application of degradable stents gradually become possible.Objective: To observe the safety of Neovas biodegradable stents versus Xience Prime(TM)drug eluting stent after percutaneous coronary intervention,and to provide a reference for the clinical application of biodegradable stents.Methods: Selected 25 patients who in line with Neovas biodegradable scaffold single group enrollment study entry criteria from January 2015 to September 2016 as trial group,which did not meet all the study exclusion criteria at the same time,implanting Neovas BRS in our hospital,as well as 12 patients who met the above criteria and implanted the Xience prime stent at the same period as the control group.All cases were followed up for 1 year.Compared the differences in the incidence of adverse cardiac events such as death,myocardial infarction and target lesion reconstruction between the two groups,and observed the main biochemical changing after implanted Neovas BRS.Results: 1.There is no death and myocardial infarction in both of the two groups during the follow up.The target lesion reconstruction rate of the Neovas group and the Xience prime were 4.0% and 8.3%,the difference was not statistically significant(P=0.597).2.The incidence of angina of the two groups were 20% and 41.7%(P=0.173),the angina hospitalization rate were 20% and 25%(P=0.597),both of them was not statistically significant.The Neovas group had lower troponin elevation rate compared with Xience prime group(20% and 41.7%),during the follow up,the difference was statistically significant(P=0.021).3.The red blood cell count in the Neovas group was reduced after percutaneous coronary intervention(P = 0.04),and the white blood cell count was increased at the same time(P=0.041),the content of LDL-C reduced significant after PCI,the difference was statistically significant.The changing of Cr,ALT,AST and Fasting bold glucose had no significate difference.Conclusion 1.Compared with the Xience prime group,the rate of target lesion reconstruction,angina and angina hospitalization was no statistically significant during follow up(P>0.05).2.Neovas group had lower troponin elevation rate compared with Xience prime group(20% and 41.7%),during the follow up,the difference was statistically significant(P=0.021).3.Neovas BRS was observed within 24 hours after the PCI of reduction of red blood cell count,white blood cell count increased,low density lipoprotein decreased(P<0.05),and liver function,serum creatinine and fasting blood glucose levels did not change significantly(P>0.05). |
PDF Full Text Request